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Abstract In vivo toxicity and absorption studies of topical
ocular drugs are problematic, because these studies involve
invasive tissue sampling and toxic effects in animal models.
Therefore, different human corneal models ranging from sim-
ple monolayer cultures to three-dimensional models have
been developed for toxicological prediction with in vitro
models. Each system has its own set of advantages and disad-
vantages. Use of non-corneal cells, inadequate characteriza-
tion of gene-expression profiles, and accumulation of geno-
mic aberrations in human corneal models are typical draw-
backs that decrease their reliability and predictive power. In
the future, further improvements are needed for verifying
comparable expression profiles and cellular properties of hu-
man corneal models with their in vivo counterparts. A rapidly
expanding stem cell technology combined with tissue engi-
neering may give future opportunities to develop new tools in
drug toxicity studies. One approach may be the production of
artificial miniature corneas. In addition, there is also a need to
use large-scale profiling approaches such as genomics, tran-
scriptomics, proteomics, and metabolomics for understanding
of the ocular toxicity.
Keywords Ocular toxicity . Corneal cell culture . ADME
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Introduction
Cornea is an effective absorption barrier for topically applied
ocular drugs, but at the same time it is the most significant
route for drug permeation to the anterior chamber [1].
Therefore, isolated animal corneas and cultured corneal epi-
thelia have been used to study drug permeability in the cornea
[2–4]. In vivo biodistribution studies require sacrification of at
least 20 animals (e.g., 5 time points, 4 eyes/point, 2 drugs or
formulations compared), typically rabbits, because non-
invasive sampling is not possible and many animals must be
killed at each time point in order to generate the concentration
curves [5–7]. The role of corneal cell models in permeability
testing has been reviewed previously [8, 9].
As a drug permeation route, the corneal cells are exposed to
the potential toxic effects of the applied drugs. Traditionally,
the corneal and other ocular toxicity has been studied in ani-
mal experiments, but such experiments (e.g., Draize test) have
been widely criticized for ethical reasons. In Draize test, the
test substances are instilled into the lower conjunctival sac of
an albino rabbit [10]. The conclusions are drawn based on the
observed changes in the anterior segment of the eye. The
possible changes include corneal opacification, conjunctival
redness, iritis, edema, and lacrimal discharge. Evaluation of
the results is subjective and dependent on the person, who is
examining the eyes. The rabbit model has also been criticized
for the differences in physiology, anatomy, and morphology
between human and rabbit eyes. In addition, the test is not
truly quantitative, and the test may cause pain and/or discom-
fort to the animals.
Ex vivo animal-basedmodels have also been used in ocular
toxicity assessment. These methods include isolated tissues
(cornea) and organs (whole eye) [11, 12]. Corneal opacity
and permeability (BCOP) assays are based on intact corneas
isolated from bovine tissues, whereas the isolated chicken eye
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(ICE) test is used to follow toxic reactions after applying the
test substance to the cornea of whole chicken eye. These
methods allow measuring of the cytotoxic effects such as
changes in opacity, fluorescein retention or permeation, tissue
swelling, and other macroscopic changes. Although normal
physiological and biochemical properties are present, these
models are suitable only for short-term (a few hours) assess-
ment of toxicity. However, assessment of toxicity with animal
tissues may not represent the conditions in the human eye.
Recently, ocular toxicity tests have been increasingly per-
formed with in vitro methods [13]. The authorities have en-
couraged researchers to develop in vitro studies, for example,
the European legislation (Directive 63/2010/EU) is based on
replacement, reduction, and refinement of animal experi-
ments. Furthermore, in 2013, the European Union banned
animal testing for cosmetics (Cosmetics Directive 76/768/
EEC). Even though the directives allow medical research with
animals, the recommendations and legislation will probably
shift toward the alternative methods.
In recent years, a variety of human corneal cell models
in vitro have been developed [4, 14–18]. In the simplest mod-
el, human corneal epithelial primary or immortalized cells are
grown in conventional cell culture wells. The more sophisti-
cated systems are based on the culture of the cells on extra-
cellular matrix-coated filters allowing generation of polarized
three-dimensional corneal models. Furthermore, cell culture
models that mimic the entire human cornea have been devel-
oped. This review gives an overview to the properties of the
corneal cell culture models used in ocular toxicity testing.
Human corneal cell models
Human corneal cell culture models have been developed for
studies of corneal permeation and barrier studies [4, 15–17],
toxicity testing [19–23], and ocular transport studies [24].
These models use primary and immortalized cell cultures
and different 3D corneal equivalents as well.
Microscopic anatomy of human cornea
The cornea is an avascular and transparent tissue between tear
film and anterior chamber. The tear film keeps the cornea
moist and protects the eye against infections [25]. The cornea
is a multilayered tissue consisting of epithelium, basement
membrane, Bowman’s layer, stroma, Descemet’s membrane,
and endothelium (Fig. 1). The epithelium has five to six cell
layers, with a total thickness of about 50 μm. The two most
anterior cell layers of the corneal epithelium are flattened and
contain tight junctions. Below these superficial cells are the
multilayered wing cells and one layer of mitotically active
columnar basal cells [18, 25]. The basement membrane (40–
60 nm) contains collagen IV, laminin, and fibronectin, and it
plays an important role in the maintenance of the corneal
epithelium [18]. Bowman’s layer/membrane (8–12 μm) is
acellular consisting of randomly arranged collagen fibers.
The corneal stroma (500 μm) consists of 2-μm-thick flattened
collagenous lamellae. The collagen fibers are mainly of hy-
drated type I collagen with interspersed glycosaminoglycans
(GAG) and some type III, V, and VI collagen [25]. Between
the lamellae lie flattened keratocytes which are located
throughout the stroma with a density of 20,000–24,000
cells/mm2 in humans. Gap junctions connect keratocytes to
their neighboring cells to maintain the structure and transpar-
ency of the stroma. Keratocytes produce extracellular matrix
proteins and can synthetize collagen for tissue repair [26–28].
Acellular Descemet’s membrane (7 μm thick) beneath the
stroma is composed of collagen fibrils. The endothelium is a
single layer of hexagonal-shaped cells with a total thickness of
about 5 μm. It covers the innermost surface of the cornea, but
it does not resist permeability of drugs to the aqueous humor.
Recently, Dua et al. [29] introduced another layer in the hu-
man cornea. This acellular layer of 10 μm exists between
Descemet’s membrane and stroma. However, so far, no other
researcher group has confirmed their finding.
Human corneal epithelial primary cell cultures
Human primary corneal epithelial cells [21, 30–37] have been
used in a wide range of basic ocular studies involving cell
attachment, cellular uptake, apoptosis, toxicity, and effects of
growth factors on epithelial cell proliferation and differentia-
tion. The primary cultures of the cells are not modified thereby
representing native corneal epithelial cells. Furthermore, the
primary cultures are easy to use when compared to 3D corneal
epithelial models and corneal equivalents (Fig. 2). Although
human primary corneal epithelial cells are commercially avail-
able from many suppliers, they are not optimal for in vitro use
due to their short life span up to about ten passages [38], but
the phenotype of the primary cells has often better match with
the in vivo tissue as compared to the modified cell lines.
Primary human corneal epithelial cells are useful in toxicity
Fig. 1 Schematic representation of the different corneal layers
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studies using various end-points (BToxicity tests with corneal
cell culture models^ section). They can be used in normal cell
culture wells or as components to generate more complex cell
models.
Immortalized human corneal epithelial cell lines
The life span of corneal primary cells can be extended using
viral immortalization techniques (e.g., recombinant SV-40-ad-
enovirus, recombinant retrovirus). Immortalized human cor-
neal epithelial cell lines, such as the HCE-T [39], CEP1 or
CEP1-17-CL4 [40], 10.014 pRSV-T [38], and HPV16-E6/E7
[41], have been generated with viral genes. Sometimes, hu-
man corneal primary cells undergo spontaneous immortaliza-
tion [42], but immortal cells may exhibit altered growth, tu-
morigenicity, and abnormal levels of proteases and cell sur-
face markers. Furthermore, immortalized cell lines have chro-
mosomal abnormalities and may contain heterogeneous cell
populations [43]. Corneal cell lines with extended life-span
offer several advantages compared to the primary cells: un-
limited renewal of the cells, more reproducible experiments,
and easier genetic manipulation. These cells may, however,
undergo different responses to the toxic chemical exposure
as their gene expression profile can differ from the normal
corneal epithelium; for example, the efflux protein expression
is increased compared to the normal corneal epithelium and
this may reduce the cellular exposure to the external chemicals
[24]. This is also a common mechanism for cancer cells to
acquire resistance to the cytotoxic agents.
The Statens Seruminstitut rabbit corneal (SIRC) cells have
also been used as a model of human corneal epithelium [17, 18],
but in fact the SIRC cells have a fibroblast phenotype [44].
Corneal cell lines are useful in toxicity studies using vari-
ous end-points, and their performance in normal cell culture
wells without differentiation was successfully correlated with
the in vivo tolerance of some drugs, excipients, and formula-
tions [22]. Only human cell lines should be used. Since pri-
mary corneal epithelial cells and cell lines are commercially
available, there is no valid reason to use SIRC cells in ocular
toxicity evaluations.
Corneal epithelial cell models on filters
When corneal epithelial cells are cultured on filters (e.g.,
Transwell), they will polarize and form a barrier that resem-
bles the normal corneal epithelium [4] enabling investigations
on chemical impact on the barrier function (Fig. 2). The dif-
ferentiation process and quality of the barrier depends on the
filter material and its coating [4]. These culture models can be
based solely on the corneal epithelial cells (primary or immor-
talized) or alternatively on three-dimensional models with cor-
neal epithelial cells and feeder cells (e.g., human-derived
Fig. 2 Schematic presentation of
various human corneal culture
models with their advantages and
limitations. Abbreviations are
endothelial cells (En), epithelial
cells (Ep), permeable support
(PS), and stromal cells (S)
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epidermal keratinocytes). Typically, the corneal epithelium is
formed after air-lift, i.e., culture on air-liquid interface [4, 18,
45–47]. Usually, the corneal epithelial models contain 3–10
epithelial cell layers, but not the stromal or endothelial layers.
In toxicity studies, these models inform only about the toxic
responses that are corneal epithelium borne.
Generation of a corneal epithelial model on a filter is a long
process, since differentiation may take several weeks and, in the
case of secondary cell lines (like HCE), the filter grown epitheli-
umdoesnot alwaysdifferentiateproperly.Thismodel has limited
advantage over a simple culture of the non-differentiated cells in
the culture wells. For example, the influence of the chemicals on
barrier function is the mechanism that can be studied on filter
grown cells, but not in the normal wells. Otherwise, there is no
proof that this more complex cell culture set-up would have an
advantage over simple culture in toxicity predictions.
Three-dimensional cornea equivalents
Three-dimensional corneal tissue equivalents are usually gen-
erated using three corneal cell types (epithelial, stromal, and
endothelial cells). The three-dimensional cornea equivalent is
built step-by-step (Fig. 2). The main advantage of these
models is the complete corneal architecture that resembles
the in vivo situation.
The first three-dimensional corneal equivalent was report-
ed in 1999 [48]. This model was consisted of epithelium,
stroma, and endothelium that were based on the immortalized
human corneal cells. This construct mimicked human cornea
in terms of morphology, expression of some markers, trans-
parency, and ion and fluid transport. Later, another corneal
equivalent model was introduced as a tool for ocular irritation
tests [49, 50]. The culture model was based on SV40-
immortalized human corneal epithelial cells, human corneal
keratocytes, and human corneal endothelial cells.
The keratocytes play an important role in 3D cell culture
models, since they are located in the stroma between the epi-
thelial and endothelial cell layers. The keratocytes maintain
the structure and transparency of the stroma. The culture me-
dia for keratocytes contain many substances, such as FBS
(~10 %), ascorbic acid, insulin, transferrin, selenium, and re-
combinant growth factors (epidermal growth factor, basic fi-
broblast growth factor, platelet-derived growth factor, and
leukemia-inhibitory factor) [28, 51, 52]. Low-level nutrition
may disturb the normal cell metabolism leading to abnormal
phenotypic changes also in the presence of serum [28, 52]. At
low serum level (equal or below 2 %), the cells retain their
keratocyte phenotype.
Three-dimensional cornea equivalents are in principle op-
timal models for corneal toxicity studies, because they mimic
the entire tissue, including the epithelium, stroma, and endo-
thelium. Even though all the layers are present, the biochem-
ical pathways and toxicological reactions may still differ from
the normal cornea. Unfortunately, the toxic responses of the
3D cornea equivalents have not been rigorously studied or
compared with the normal cornea. Therefore, the true benefits
of these complex models in comparison with the simpler
models are still open. One potential advantage is related to
the studies with erosive compounds, since monitoring of cor-
neal erosion requires intact corneal tissue.
Corneal endothelial cell models
Thecornealendotheliumhasanimportant rolein themaintenance
of thehealth, but humancorneal endothelial cells donotnormally
undergomitosis in vivo because these cells have arrested into the
G1-phase of the cell cycle [53]. Therefore, the cell density gradu-
ally decreases with age [54], and these cells recover poorly from
the damages. Therefore, the corneal endothelium is an important
cell type from a toxicological point of view.
Isolated human corneal endothelial cells are able to
proliferate only for a few passages under certain in vitro
conditions. Increased cell proliferation is achieved using
insulin, growth factors (nerve growth factor, epithelial
growth factor, and basic fibroblast growth factor), bovine
pituitary extract, ascorbic acid, serum, and mitogens
[55–57]. Chondroitin sulfate, one of the GAGs in the hu-
man cornea, is also used in the media [57], since it acts as
a scaffold material of extracellular matrix (ECM) template
that is needed for proper cell growth and organization
[58]. Kim et al. [57] compared four different media for
corneal endothelial cell culture. Traditional human corneal
endothelial cell medium with FBS, epidermal growth fac-
tor, basic fibroblast growth factor, and chondroitin sulfate
was the best medium in terms of stem cell-associated pro-
tein expression, cell proliferation, and migration.
However, the cel ls become elongated and more
fibroblast-like than in the stem cell media that was more
appropriate for maintaining the correct cell shape and
functionality. Fibronectin-collagen, laminin, and collagen
type I are often used as a substrata for the endothelial cells
[57, 59–61]. These compounds have influence on cell ad-
hesion, proliferation, and migration.
In that case, donor-to-donor variability and culture medium
composition have great impact on growth rate, proliferation ca-
pacity, andmorphology of the cells [56]. Proliferation activity of
human primary corneal endothelial cells depends on age of do-
nors [62]. Age-related nuclear oxidative DNA damage decreas-
ing the proliferative capacity of the cells [63]. Sometimes, cor-
neal endothelial cell preparation may be contaminated by pro-
liferative stromal fibroblasts leading to batch-to-batch variation
in the primary cell cultures. To increase the life span of these
cells, immortalized human corneal endothelial cell lines have
been established by telomerase engineering [64]. These immor-
talized human corneal endothelial cells had endothelial
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hexagonal morphology, and they were able to proliferate more
than 70 passages without signs of senescence.
Corneal endothelial cells are a usefulmodel when endothelial
toxicity is specifically studied, but ocular irritation is not neces-
sarily related to the endothelium that is located deeper in the cor-
neal tissue.
Corneal stem cells
Corneal integrity and function depend on the self-renewing
properties of the corneal epithelial cells. Fully differentiated,
superficial cells of the corneal epithelium are continuously
shed from the ocular surface so that the complete turnover of
the corneal epithelium takes place in 7 days. During that time,
basal cells migrate upward from the basal layer, and differen-
tiate into wing cells and superficial cells [65]. Corneal stem
cells serve as an important source of new basal cells.
Different types of stem cells exist in the corneal epithelium,
stroma, and endothelium [66–69]. For epithelial stem cells, the
main hypothesis suggests that the epithelial stem cells are located
in the corneal limbus that is a transition zone between the corneal
and conjunctival epithelia [66, 67, 70, 71]. Experimental evidence
suggests thatauniquemicroenvironment in the limbalpalisadesof
Vogtmay be responsible for themaintenance and function of cor-
neal stem cells [72, 73]. An alternative hypothesis proposes that
stem cells are located in the basal layer of the corneal epithelium
[74], but most corneal stem cell research has been focused on
limbal stem cells. There is also some experimental evidence
supporting the existence of stem cells in the corneal stroma and
endothelium[69,75,76].Asfarasweknow,therearenoreportson
theutilizationofhumancornealstemcells in toxicologicalmodels.
Tissue engineering applications for corneal cells
Tissue engineering approaches utilize cellular engineering and
biomaterials to generate artificial tissues for transplantation.
Similar approaches can be used to develop cell models for
drug and chemical testing.
Ingeneral, suitablebiochemical factorsof themediummustbe
combinedwithabiomaterial scaffold inwhich thecells aregrown
[77] (Fig. 3). Three-dimensional cell constructs shouldmimic the
target tissue toachieve thedesiredfunctionality. In thehumaneye,
Fig. 3 Basic steps in tissue
engineering techniques for 3D
biofabricated cornea formation.
Isolated or cultured cells can be
printed in the desired format and
then further grown as layers or
cultured in bioreactor for
characterization and use in
toxicological testing
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cell-basedandscaffold-basedcornealengineeringhavebeenused
in corneal transplantation [78]. For example, grafts of autologous
limbal stemcells on fibrin [79] or on amnioticmembrane [80, 81]
have been used to restore the damaged corneal surface. In animal
models, collagen, amniotic membrane with gelatin, and poly(N-
isopropylacrylamide) (PNIPAAm) have been used for tissue en-
gineering of corneal endothelium [82]. Thermo-sensitive
PNIPAAm is a promising polymer [83], since a temperature
change from 37 to 20 °C modifies its structure thereby releasing
intact cell sheets with extracellular matrix from the PNIPAAm
support [84].Tissue structure isnotdamaged,becauseproteolytic
enzymes are not needed [85]. This techniquemay open newpos-
sibilities to develop corneal epithelia and corneal equivalents by
harvesting and layering frombottom to top human corneal endo-
thelial, stromal, and epithelial cell sheets. In multi-layered con-
struct,distinctcell sheetsmayspontaneously integrate resulting in
a corneal in vivo tissue substitute.
Tissue engineering methods have also limitations. For exam-
ple, synthetic matrix materials may have unfavorable properties,
such as sub-optimal mechanical properties and inadequate
support of cell growth [86]. The cell source is the greatest un-
certain feature in corneal tissue engineering. Quality of limbal
stem cells and primary cells (epithelial, endothelial) depends on
the donor tissue leading to variations in the proliferation, cell
density, and phenotype of resulting cells in the culture [87, 88].
Human embryonic stem cells and induced pluripotent stem
cells (iPSC) represent another potential cell source. Under
defined conditions, these cells can proliferate indefinitely
and maintain their pluripotent phenotype thereby providing
potential to generate any cell type [89]. Increasing the avail-
ability of human embryonic stem cell lines and iPSC lines
may provide a basis of new type of organotypic corneal
models for drug toxicity testing. These developments to-
gether with the advances in technologies (e.g.,
bioprinting) offer opportunities to generate 3D
organotypic corneal cell cultures [90]. The bioprinted
and miniaturized corneas could become tools for ocular
toxicity testing (Fig. 4). Currently, only relatively simple
and thin structures of living cells and extracellular ma-
trix can be printed in 3D format.
Fig. 4 Bioprinting and
maturation of miniature corneas
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Bioprinting 3D is still a relatively new technology that needs
further development. Challenges include optimization of print-
ing process and control of the differentiation of stem cells in 3D
culture. It is necessary to understand the mechanisms of cellular
damage and behavior in printed formats [90, 91]. Printable liq-
uid biological materials are needed to enable controlled cell
differentiation [92]. In principle, combination of modern tissue
engineering and stem cell technology could enable successful
corneal construction for drug and chemical testing.
However, rigorous testing is needed to validate such
models as predictors of ocular toxicity. Currently, the toxico-
logical value of the engineered tissue or bioprinted cell models
of the cornea is not known.
Optimization of the differentiation of corneal
epithelial cells
Culturing process
Morphology and functionality of the corneal cell culture mod-
el should be comparable to the normal cornea. The culture
conditions should mimic the conditions in vivo in terms of
pH, osmolality, temperature, oxygen levels, CO2 concentra-
tion, and nutrition [8]. Permeable support and co-culture sys-
tems, an air-liquid interface, and culture medium components
are the main parameters that are used to control differentiation
of corneal epithelial cells (Table 1).
Corneal epithelial cells have been cultured in serum-
containing media with growth factors, agents promoting cel-
lular proliferation and differentiation, cell attachment factors,
and nutrients. However, serum may disturb proliferation and
differentiation of corneal epithelial cells [103], since it
contains unknown growth inhibitors and activators.
Disturbed differentiation might lead to a sub-optimal cell
model that does not mimic the normal corneal epithelium
leading to a risk of decreased reliability of toxicological pre-
dictions. Therefore, defined serum-free culture conditions
have been developed [41, 104, 105]. In these conditions,
Ca2+, ascorbic acid, hydrocortisone, retinoic acid, and
transforming growth factor-α are crucial ingredients to sup-
port the differentiation of corneal epithelial cells (Table 2).
However, optimal culture conditions should be established
individually for each cell line. There are also commercial
serum-free-defined culture media for epithelial cell cultures
(Epilife®, Life Technologies).
Differentiation markers for corneal epithelium
Differentiation of corneal epithelial cells is often monitored with
the expression of markers that have been derived from the pri-
mary corneal epithelial cells (Table 2). The markers are impor-
tant in the assessment of the cell differentiation, but they are not
necessarily useful as toxicological marker. However, the epithe-
lial barrier integrity can be a useful end-point, because loosening
of the barrier may lead to in vivo exposure of the sensitive
corneal endothelium to toxic chemicals. The barrier integrity
of corneal epithelial cultures is verified using measurement of
transepithelial electrical resistance (TEER) and permeability of
paracellular permeants (e.g., mannitol, 6-carboxyfluorescein) [4,
18, 38, 47]. TEER is an indicator for ionic (Na+ and Cl−) per-
meability of the intercellular tight junctions [106]. Corneal epi-
thelial cells are considered to have proper tight junctions when
TEER recordings are at least 400 Ω cm2 [8], but in general it is
better to use TEER and paracellular permeability experiments in
combination to characterize the barrier of corneal cell models
Table 1 Important components and their function in differentiation of corneal epithelial cells in culture models
Component Function References
Permeable support systems
Laminin, collagen (type I), fibronectin Promoting differentiation and cell attachment [4, 35, 36]
Amniotic membrane Attachment and differentiation of cells [93]
Insert filters Polarization of the cells, cells can be fed from the basolateral side [4, 8]
Coculture systems
Fibroblasts Feeder layer, provoking differentiation of cells [94]
Air-liquid interface Inducing differentiation [4, 95]
Supplements
Ca2+, ascorbic acid, hydrocortisone, and retinoic acid Strengthening barrier function in serum free medium [96]
Isoproterenol, cholera toxin Enhancing cell proliferation [97]
Dimethyl sulfoxide Differentiation agent [98]
Epidermal growth factor Increasing adhesion, proliferation, and spreading [99]
Insulin, insulin growth factors 1 and 2 Promoting proliferation, inhibiting apoptosis [100]
Selenium Preventing oxidative stress [101]
Transforming growth factor-α Stimulating cell migration [102]
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[4]. In addition, molecular weight markers have been used to
estimate paracellular porosity and average pore size of isolated
cornea and corneal epithelium [47]. This approach gives more
complete view on the corneal epithelial barrier. However, uni-
versal characterization of the cultured corneal epithelium with
transcriptome analysis revealed substantial differences between
the culture model and normal human corneal epithelium [107].
Toxicity tests with corneal cell culture models
Corneal cell culture models are developed to reduce, refine,
and replace animal testing. At the moment, the cell culture
models do not replace all animal tests, but they are useful in
the reduction and refinement of animal experiments. The fol-
lowing sections inform about ocular toxic reactions and the
role of the cell culture test systems as predictive models.
Toxic reactions
Chemical exposure may cause eye irritation that is a painful
reaction involving direct action on the pain receptors [115].
Irritation may result in the damage of corneal tissue [116]. The
extent of corneal injury depends on the toxicity of the chem-
ical. Typical irritating agents are cationic, anionic and non-
ionic surfactants, aldehydes, acids, alcohols, and alkaline sub-
stances. Slight irritants injure corneal epithelium, mild and
moderate irritants injure corneal epithelium and superficial
stroma, and severe irritants may cause damage in all corneal
layers. Typical corneal responses to irritation include inflam-
mation, activation, and migration of keratocytes, fibrosis, and
neovascularization [117]. Toxic effects in vascularized con-
junctival tissue include redness, swelling (chemosis), and dis-
charge [10].
Drugs andmetabolites may also induce toxic responses that
are not related to direct irritation. Drug-induced toxicity is a
complex phenomenon that reflects interactions with target and
off-target molecules (e.g., proteins, RNA, and DNA) and
alterations of metabolic and signal transduction pathways that
may lead to adverse effects [118, 119]. There are huge num-
bers of potential alterations that may take place, and determi-
nation of the molecular mechanisms of toxic actions is a chal-
lenging task.
Toxicity assays and end-points
The principle of toxicity assays in vitro is to expose cells to
various drug concentrations over a certain time. The cells are
monitored after the incubation and compared to the normal
state.
Cell viability is themost straightforward end-point in toxicity
assays. Chemicals may cause cellular injury that induces cyto-
toxicity via apoptotic and/or necrotic pathways. Common via-
bility assays are based on the integrity of cellular membrane or
metabolic activity of the cells. These factors are analyzed using
colorimetric-, fluorometric-, or luminescence-based methods
[120, 121]. Typically, the rank order of assay sensitivity follows
the pattern: luminescence > fluorescence > colorimetry
[121–123]. The measurement of the cell membrane integrity is
a common method assessing cellular cytotoxicity. Propidium
iodide, Trypan blue, calcein-AM, and lactate dehydrogenase
are commonly used biomarkers for cell membrane integrity
[120, 121, 124] (Fig. 5). Propidium iodide and Trypan blue
are unable to cross plasma membrane of viable cells, but per-
meation can take place through damaged cell membranes
resulting in strong nuclear staining of the cells. The lipophilic
ester, calcein-AM, permeates into the cells where esterases con-
vert it to fluorescent calcein that is entrapped within the viable
cells [124]. Conversion and entrapment do not take place in
non-viable cells with leaking plasmamembrane. Another option
is to determine leakage of intracellular components through the
plasma membrane [120, 121]. Lactate dehydrogenase can leak
out from the cells only if the plasma membrane has been dam-
aged and its activity in the cell culture medium can be conve-
niently measured with colorimetric, fluorometric, or lumines-
cence assays (Fig. 5).
Table 2 Markers used in evaluation of corneal epithelial-specific differentiation in corneal cell models
Determinants of differentiation Markers References
Cellular morphology Cobblestone morphology, multilayered well-stratified epithelium, microvilli
tight junctions, desmosomes
[4, 39]
Basement membrane components Collagen α5(IV), laminin-1, laminin-5, fibronectin, type VII collagen [108]
Cytokines Interleukins IL-lα, IL-lβ, IL-6, IL-8, tumor necrosis factor α [40]
Growth factors Transforming growth factors α, β1 and β2, epidermal growth factor, platelet-
derived growth factor
[40]
Keratins Keratin 3 (K3, 64-kDa) [67]
Keratin 12 (K12, 55-kDa)
Metabolic enzymes Cytochrome P450, glutathione transferase, N-acetyltransferase, sulfotransferase [109]
Transcription factors Pax6, FoxC1 [110, 111]
Tight junction proteins Claudins, occludin, ZO-1, ZO-2 [112–114]
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Cytokines are often used as biomarkers of cytotoxicity
[125]. These signaling molecules have a wide variety of cel-
lular functions, and they are stimulated when cellular homeo-
stasis is altered. Toxic chemicals can induce signaling path-
ways involved in cytokine release, and cytokine levels can be
measured by bioassays or immunoassays (Fig. 5).
Toxic compounds may cause effects on the cellular
metabolic activities and, therefore, such changes are
useful indicators of cellular toxicity [121]. One of the
indicators is ATP metabolism, because the loss of mem-
brane integrity leads to rapidly decreasing levels of ATP
that can be detected with fluorescence or luminescence
assays. Other widely used metabolic indicators report
the activity of cellular oxidation-reduction systems
(e.g., MTT, XTT, MTS, resazurin, WST-1) [120, 121,
126]. Unlike dead cells, viable cells reduce the dyes
to colored products [124]. The amounts of the colored
products are directly proportional to the number of via-
ble cells. Toxic processes, like biological cellular path-
ways in general, are complicated and highly interactive.
Therefore, toxicity assay methods are shifting from sin-
gle targets to multiplex formats. The multiplex assays
can detect multiple biomarkers (viability, cytotoxicity,
apoptosis) simultaneously in the same sample [121].
Therefore, more information can be gained from the
pathways of necrosis, apoptosis, oxidative stress, and
growth arrest. At present, there are no reports on the
use of multiplex formats in corneal toxicity assessment.
Many single parameter assays have been used in the
human corneal toxicity studies (e.g., MTT, propidium
iodide, calcein-AM) [22].
ABC efflux transporters are an important part of the cellu-
lar protection against toxic agents. They also limit distribution
of many clinical drugs into cells [127]. Interestingly, sub-
strates and inhibitors of ABC transporters may interfere with
the MTT assay, because the dye is also a substrate to such
transporters [128]. Consequently, exposure to the substrates
and/or inhibitors of ABC efflux proteins may increase the
apparent viability of cells in the MTT assay thereby
underestimating the cellular toxicity. Furthermore, other phys-
ical or chemical characteristics such as the color of the drug or
the ability to reduce used substrate can interfere with toxicity
experiments and thus give incorrect results [129].
Overall, interpretation of toxicity assay results can be com-
plicated. Toxicity can result from various cellular events, such
as changes in enzymatic activity, differentiation, proliferation,
morphology, cell functions, and cell detachment [130, 131].
Insights into the biochemical mechanisms may be obtained
through systems approaches (proteomics, transcriptomics,
metabolomics) that are emerging tools in predictive toxicolo-
gy [118, 132]. Furthermore, the data obtained from Bomics^
technologies can be combined with structure-based informa-
tion on toxicity from computational in silico models, resulting
in so-called hybrid toxicity modeling systems [133].
Structure-based predictive toxicity models could be based on
the fingerprints, archetypical changes in the biochemical path-
ways that are caused by a certain chemical class leading to
defined toxic symptoms. Such information would be very
useful, but it requires plenty of experimental work before such
models can be established for corneal toxicity. So far, such
models have not been utilized to assess the corneal toxicity.
Traditional simple end-point assays do not yield mechanistic
insights, like systems biology, but they are attractive due to
their simplicity. At the moment, the Bomics^ techniques are
far too expensive, slow, and resource intensive for the practi-
cal assessment of corneal toxicity.
Fig. 5 Categories of cellular
toxicity assays and their end-
points
668 Drug Deliv. and Transl. Res. (2016) 6:660–675
Toxicity tests with monolayer cultures of human corneal
epithelial cells
Amonolayer culture assay with primary or immortalized cells
grown on plastic wells is the simplest corneal cell toxicity
model. Human primary corneal epithelial [19, 21], and im-
mortalized corneal epithelial cells [19, 22, 134, 135] have
been used to evaluate toxicity of natural tear substitutes, var-
ious ophthalmic drugs, and pharmaceutical excipients. It is
expected that a simple culture of non-differentiated corneal
cells should predict the toxic reactions in the intact cornea
in vivo. Saarinen-Savolainen et al. [22] showed correlation
between cellular toxicity in the corneal epithelial cell line
and the corneal toxicity in vivo. This report also paid attention
to the concentrations of in vitro and in vivo exposure.
Only a few studies have compared the toxicity of ophthal-
mic drugs in corneal and non-corneal cells. Cheong and co-
workers [19] tested the susceptibility of primary and immor-
talized corneal and retinal cells, human skin keratinocytes, and
fibroblasts to eight β-blockers (propranolol, alprenolol, aten-
olol, labetalol, metoprolol, pindolol, timolol, bisoprolol). The
standard MTT assay did not reveal any differences in the tox-
icity of β-blockers in keratinocytes, fibroblasts, and human
corneal epithelial cell lines.
Monolayers of human primary or immortalized corneal
epithelial cell cultures do not adequately represent the whole
cornea with extensive cell-cell and cell-matrix interactions.
These factors can have a marked influence on the toxicity of
substances. Furthermore, there is a great inter-laboratory var-
iation in the toxicity data from corneal cell monolayer studies
[136]. An increasing number of researchers have questioned
the validity of studying toxicity in monolayer cell cultures,
and therefore, there has been a growing tendency towards
more complex and sophisticated cell models.
Toxicity tests with human corneal endothelial cells
Human corneal endothelial cells have been used to eval-
uate toxicity of ophthalmic solutions, drugs, and
cleaning procedures in ophthalmic surgery [137–140].
Human corneal endothelial cells are the best choice for
this kind of in vitro safety studies for intra-cameral
agents. Anti-glaucoma drug formulations with preserva-
tives were more toxic than preservative-free formula-
tions. However, dilution of these formulations up to
100 times diminished the cytotoxicity substantially sug-
gesting that the endothelial toxicity risk in vivo is small.
Toxicity results of ophthalmic solutions suggest that the
survival rates of primary corneal endothelial cells are in
general comparable to those of bovine and rabbit corne-
al epithelial and SIRC cell lines, but the rank-order is
compound dependent [137, 141].
Toxicity tests with three-dimensional cell culture models
There is a growing interest to use corneal epithelial models in
which the cells are cultured on a synthetic micro-porous mem-
brane at air-liquid interface. This results in a multi-layered
epithelium with tight junctions on the apical side [4].
Usually, these models have been developed for in vitro drug
permeation studies, but it is possible to use them also for
toxicity assessment. The European Union Reference
Laboratory for alternatives to animal testing (EURL
ECVAM) has not fully validated any corneal cell model for
eye irritation tests yet.
The commercially available EpiOcular cell culture system
by MatTek has been used in toxicity and irritancy tests. It
consists of human skin-derived epidermal keratinocytes that
have been cultured to form stratified squamous epithelium
[23]. Although EpiOcular is based on non-corneal cells, it
has relatively good ability to find ocular irritants, non-irritants,
and to discriminate them from each other. The model was
tested with 105 different chemicals, and EURL ECVAM con-
cluded that the model was predictive, even though the agency
had some reservations [142]. According to ESAC,
EpiOcular™ EIT had satisfied the requirements regarding
transferability, reproducibility, and predictive capacity in the
assessment of irritation potential of chemicals. ESAC also
pointed out that confidence in the test method would be in-
creased if supplementary investigations confirm that the meth-
od correctly classifies a representative sample of products
from different sectorial classes as defined in REACH. It is
unlikely that this model would be useful in more subtle forms
of toxic reactions (e.g., inflammatory responses), because epi-
dermis and corneal epithelium are quite different tissues.
Another commercially available reconstructed human cor-
neal epithelial model (SkinEthic HCE model) was used to test
435 substances from the cosmetic industrial domain including
surfactants, polymers, fatty derivatives, silicons, dyes, sol-
vents, natural extracts, and preservatives [20]. Later, transfer-
ability, reproducibility, and predictive capacity of this model
were investigated in studies performed in three laboratories
using both liquids and solids [129, 143]. The overall accuracy
of the model was 83.7 % (200 chemicals), specificity 72.1 %
(103 chemicals), and sensitivity of 95.2 % (97 chemicals)
[143]. However, EURLECVAMStatus Report concluded that
SkinEthic™ HCE would require optimization and further val-
idation [142].
Recently, another commercial cell model (LabCyte
CORNEA-MODEL; Japan Tissue Engineering Co., Ltd.)
has been tested [144]. In this model, differentiated human
corneal epithelium was obtained on filter substrate. Sixty-
one chemicals were tested, and the model appeared to be a
relevant and reliable predictor of in vivo toxicity.
Jung et al. [145] reconstructed human corneal epithelial
model (MCTT HCE model) from primary human limbal
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epithelial cells that were obtained from human subjects under-
going corneal transplantation. The MCTT HCE model de-
velops morphology and biomarkers similar to intact human
corneal epithelium within 7 days of cultivation on a polycar-
bonate filter. This in vitro human corneal epithelial model
showed high predictive ability of irritant and non-irritant com-
pounds. Advanced 3D human corneal model that includes
stromal matrix with incorporated immortalized keratocytes
and with immortalized human corneal epithelial cells (HCE)
was recently reported [146]. This model is an intermediate
step between a corneal epithelial model and full 3D corneal
equivalent. This model was tested using 20 chemicals with
different eye-irritating potential in two independent laborato-
ries. The model showed predictive capability, but the levels
were less than those with simpler models.
In principle, complex 3D tissue models should mimic hu-
man cornea better than simple models. So far, the difference is
not obvious. In addition to the macroscopic appearance of the
models, they should mimic also the cellular biological net-
works in the corneal cells. This aspect has not been studied
in detail, but one example showed substantial difference in the
systems biology of a corneal epithelial cell model compared to
normal human ex vivo corneal epithelium [107].
Similarity between the cell models and human cornea
HCE-T cells (simian virus SV-40-immortalized human corne-
al epithelial cells) have been used widely in ophthalmology,
since they were published for the first time [38, 39]. However,
array-based comparative genomic hybridization analysis dem-
onstrated that genomic content of these cells is altered, and
heterogeneous cell populations exist in monolayer cultures
[43]. Furthermore, high-density oligonucleotide microarray
analysis revealed significant differences between the gene ex-
pression profiles of the 3D HCE-T model and freshly isolated
human corneal epithelium [107]. HCE-T cells form a strati-
fied, compact structure that resembles in many ways native
human corneal epithelium (tight barrier with TEER value
>300 Ω cm2, desmosomes, tight junctions, apical microvilli),
but still 22 % of the genes were over-expressed and 14 %
under-expressed. It has been shown earlier that cytokeratin
expression of immortalized human corneal epithelial cells on
filters does not resemble native cornea [147]. We should also
note that the same cell line may show different gene expres-
sion patterns in distinct laboratories [136]. This aspect of SV-
40 immortalized cells may also influence the behavior of the
hemi-cornea model [146].
As described earlier in this review, some human corneal cul-
ture models, such as EpiOcular [23], SkinEthic HCEmodel [20,
148], LabCyte CORNEA-MODEL [144], and MCTT HCE
model [145], have been used in in vitro irritation studies with
rather good correlations to in vivo irritation. EpiOcular contains
human skin-derived epidermal keratinocytes, and no corneal
cells at all [23]. Therefore, it is unlikely that this would be an
optimal model for ocular toxicity testing, whereas the LabCyte
CORNEA-MODEL is based on normal human corneal epithe-
lial cells [144], and the MCTT HCE model was constructed
using human limbal epithelial cells [145]. Thus, these models
may be closer to human cornea than EpiOcular and SkinEthic
HCE models. Anyway, no commercial model has been charac-
terized at systems biology level for gene expression.
Direct corneal irritation after topical administration is a
strong acute effect, and, therefore, it is not surprising that
toxicity of the irritant compounds becomes evident even in
non-corneal cells [23] or monolayer cultures of corneal epi-
thelial cell lines [22]. However, side effects of ocular drug
candidates are milder, and they may show distinct mecha-
nisms and long-term effects. Studies of these phenomena re-
quire cell models that are closely mimicking the human cor-
nea. Previously, we demonstrated that commercial epidermal
cell models with poorly developed barrier properties showed
poor correlation with in vivo skin irritation, whereas a skin
model with decent barrier predicted in vivo adverse effects
much more reliably [149, 150].
Drug exposure time is a crucial difference between the cell
culture experiments and the in vivo situation after topical ad-
ministration. After topical ocular administration, the drug con-
centration in the tear fluid drops rapidly within a few minutes,
but the drug may be applied continuously using multiple dos-
ing regimen [1]. Drug toxicity is a function of exposure (con-
centration, dose), and the concentrations in the pre-corneal
fluid are changing rapidly. The concentration range can be
estimated based on the literature or simulated [151]. It is not
well understood how this aspect influences the reliability of
toxicological predictions, but several drug concentrations and
exposure times should be used in vitro to mimic the exposure
conditions in vivo [121].
Conclusions
Various cell models with different complexity have been used
in the past. Some organotypic 3Dmodels have been thorough-
ly evaluated, but not yet validated for toxicity predictions.
Some simple models seem to be useful for toxicity screening,
and their advantages include speed and low cost. More com-
plex 3D models have some specific advantages, such as mon-
itoring of the potential toxic effects in non-epithelial cell types
(endothelial cells, keratocytes) and effects on the structure of
the tissues (e.g., erosion effects).
The mechanisms of corneal toxicity are not well under-
stood, and this makes translation of the results to the human
eye in vivo difficult. Currently, the predictive capacity of the
cell models is usually evaluated using the Draize test as gold
standard, but the relevance of the Draize test as a predictor of
human corneal toxicity is not clear either.
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One of the challenges for the future will be to further improve
human corneal culture models in such a way that they resemble
native human cornea as closely as possible. Integration of
bioprinting with modern tissue engineering may provide such
progress, but this field is at an early stage and no clear guidelines
on the best practices are available. More effort is needed toward
better characterization of constructed human corneal culture
models using multiplexed or systems biology level approaches.
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